277 related articles for article (PubMed ID: 34045232)
1. Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Jo U; Senatorov IS; Zimmermann A; Saha LK; Murai Y; Kim SH; Rajapakse VN; Elloumi F; Takahashi N; Schultz CW; Thomas A; Zenke FT; Pommier Y
Mol Cancer Ther; 2021 Aug; 20(8):1431-1441. PubMed ID: 34045232
[TBL] [Abstract][Full Text] [Related]
2. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
3. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
[TBL] [Abstract][Full Text] [Related]
5. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
6. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Lücking U; Wortmann L; Wengner AM; Lefranc J; Lienau P; Briem H; Siemeister G; Bömer U; Denner K; Schäfer M; Koppitz M; Eis K; Bartels F; Bader B; Bone W; Moosmayer D; Holton SJ; Eberspächer U; Grudzinska-Goebel J; Schatz C; Deeg G; Mumberg D; von Nussbaum F
J Med Chem; 2020 Jul; 63(13):7293-7325. PubMed ID: 32502336
[TBL] [Abstract][Full Text] [Related]
7. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
8. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.
Gorecki L; Andrs M; Rezacova M; Korabecny J
Pharmacol Ther; 2020 Jun; 210():107518. PubMed ID: 32109490
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Thomas A; Takahashi N; Rajapakse VN; Zhang X; Sun Y; Ceribelli M; Wilson KM; Zhang Y; Beck E; Sciuto L; Nichols S; Elenbaas B; Puc J; Dahmen H; Zimmermann A; Varonin J; Schultz CW; Kim S; Shimellis H; Desai P; Klumpp-Thomas C; Chen L; Travers J; McKnight C; Michael S; Itkin Z; Lee S; Yuno A; Lee MJ; Redon CE; Kindrick JD; Peer CJ; Wei JS; Aladjem MI; Figg WD; Steinberg SM; Trepel JB; Zenke FT; Pommier Y; Khan J; Thomas CJ
Cancer Cell; 2021 Apr; 39(4):566-579.e7. PubMed ID: 33848478
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
11. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Konstantinopoulos PA; da Costa AABA; Gulhan D; Lee EK; Cheng SC; Hendrickson AEW; Kochupurakkal B; Kolin DL; Kohn EC; Liu JF; Stover EH; Curtis J; Tayob N; Polak M; Chowdhury D; Matulonis UA; Färkkilä A; D'Andrea AD; Shapiro GI
Nat Commun; 2021 Sep; 12(1):5574. PubMed ID: 34552099
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
Hall AB; Newsome D; Wang Y; Boucher DM; Eustace B; Gu Y; Hare B; Johnson MA; Milton S; Murphy CE; Takemoto D; Tolman C; Wood M; Charlton P; Charrier JD; Furey B; Golec J; Reaper PM; Pollard JR
Oncotarget; 2014 Jul; 5(14):5674-85. PubMed ID: 25010037
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
17. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury A; Hall S; Curtin N; Drew Y
Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
[TBL] [Abstract][Full Text] [Related]
18. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R; Fokas E; Reaper PM; Charlton PA; Pollard JR; McKenna WG; Muschel RJ; Brunner TB
Cancer Biol Ther; 2012 Sep; 13(11):1072-81. PubMed ID: 22825331
[TBL] [Abstract][Full Text] [Related]
19. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Talele S; Zhang W; Burgenske DM; Kim M; Mohammad AS; Dragojevic S; Gupta SK; Bindra RS; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2021 Dec; 379(3):343-357. PubMed ID: 34556535
[TBL] [Abstract][Full Text] [Related]
20. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]